This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Russell, J. S. Articles by Tofilon, P. J. Search for Related Content PubMed PubMed Citation Articles by Russell, J. S. Articles by Tofilon, P. J.

Gleevec-Mediated Inhibition of Rad51 Expression and Enhancement of Tumor Cell Radiosensitivity

Molecular Radiation Therapeutics Branch [J. S. R., K. B., W. E. B., M. A. C., K. A. O., P. J. T.] and Radiation Oncology Branch [K. C.], Radiation Oncology Science Program, National Cancer Institute, Bethesda, Maryland 20892

Rad51 is an essential component of the homologous DNA repair pathway and has been implicated as a determinant of cellular radiosensitivity. Gleevec is a relatively specific inhibitor of c-Abl, a tyrosine kinase that can play a role in the regulation Rad51. The aim of this study was to determine the effects of Gleevec on Rad51 levels and the radiosensitivity of two human glioma cell lines and a nonimmortalized normal human fibroblast cell line. Exposure of both glioma cell lines to radiation resulted in an increase in Rad51 expression; Gleevec treatment alone reduced Rad51 expression. When glioma cells were pretreated with Gleevec, radiation-induced Rad51 expression and nuclear foci formation were reduced. Accordingly, pretreatment of the glioma cells with Gleevec resulted in an enhancement in their radiosensitivity. These data indicate that Gleevec enhances radiation-induced tumor cell killing and suggest that the mechanism involves the reduction in Rad51 levels. In contrast to the glioma cell lines, radiation or Gleevec treatments had no effect on Rad51 expression or foci formation in the normal fibroblast cells. Consistent with these observations, Gleevec did not modify the radiosensitivity of the normal cell line. These results suggest that Rad51 expression is subject to different regulatory processes in the glioma and normal cell lines and further suggest that Rad51 may be an appropriate target for selectively enhancing the radiosensitivity of brain tumor cells.

This article has been cited by other articles:

				J.-C. Ko, S.-C. Ciou, J.-Y. Jhan, C.-M. Cheng, Y.-J. Su, S.-M. Chuang, S.-T. Lin, C.-C. Chang, and Y.-W. Lin Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase-AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non-Small Cell Lung Cancer Cells Mol. Cancer Res., August 1, 2009; 7(8): 1378 - 1389. [Abstract] [Full Text] [PDF]

				G. Frosina DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res., July 1, 2009; 7(7): 989 - 999. [Abstract] [Full Text] [PDF]

				A. Choudhury, H. Zhao, F. Jalali, S. AL Rashid, J. Ran, S. Supiot, A. E. Kiltie, and R. G. Bristow Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity Mol. Cancer Ther., January 1, 2009; 8(1): 203 - 213. [Abstract] [Full Text] [PDF]

				C. M. Hine, A. Seluanov, and V. Gorbunova Use of the Rad51 promoter for targeted anti-cancer therapy PNAS, December 30, 2008; 105(52): 20810 - 20815. [Abstract] [Full Text] [PDF]

				J.-C. Ko, S.-C. Ciou, C.-M. Cheng, L.-H. Wang, J.-H. Hong, M.-Y. Jheng, S.-T. Ling, and Y.-W. Lin Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells Carcinogenesis, July 1, 2008; 29(7): 1448 - 1458. [Abstract] [Full Text] [PDF]

				F. Huguet, N. Giocanti, C. Hennequin, M. Croisy, E. Touboul, and V. Favaudon Growth inhibition by STI571 in combination with radiation in human chronic myelogenous leukemia K562 cells Mol. Cancer Ther., February 1, 2008; 7(2): 398 - 406. [Abstract] [Full Text] [PDF]

				D. A. Reardon, A. Desjardins, J. J. Vredenburgh, S. Sathornsumetee, J. N. Rich, J. A. Quinn, T. F. Lagattuta, M. J. Egorin, S. Gururangan, R. McLendon, et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: Phase 1 trial in adults with malignant glioma Neuro-oncol, January 1, 2008; 10(3): 330 - 340. [Abstract] [Full Text] [PDF]

				S. C. Short, C. Martindale, S. Bourne, G. Brand, M. Woodcock, and P. Johnston DNA repair after irradiation in glioma cells and normal human astrocytes Neuro-oncol, October 1, 2007; 9(4): 404 - 411. [Abstract] [Full Text] [PDF]

				I. F. Pollack, R. I. Jakacki, S. M. Blaney, M. L. Hancock, M. W. Kieran, P. Phillips, L. E. Kun, H. Friedman, R. Packer, A. Banerjee, et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: A Pediatric Brain Tumor Consortium report Neuro-oncol, April 1, 2007; 9(2): 145 - 160. [Abstract] [Full Text] [PDF]

				J. Baranowska-Kortylewicz, M. Abe, J. Nearman, and C. A. Enke Emerging Role of Platelet-Derived Growth Factor Receptor-{beta} Inhibition in Radioimmunotherapy of Experimental Pancreatic Cancer Clin. Cancer Res., January 1, 2007; 13(1): 299 - 306. [Abstract] [Full Text] [PDF]

				D. A. Reardon, M. J. Egorin, J. A. Quinn, J. N. Rich Sr, I. Gururangan, J. J. Vredenburgh, A. Desjardins, S. Sathornsumetee, J. M. Provenzale, J. E. Herndon II, et al. Phase II Study of Imatinib Mesylate Plus Hydroxyurea in Adults With Recurrent Glioblastoma Multiforme J. Clin. Oncol., December 20, 2005; 23(36): 9359 - 9368. [Abstract] [Full Text] [PDF]

				P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, A. M. Chinnaiyan, and P. M. Harari Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva) Cancer Res., April 15, 2005; 65(8): 3328 - 3335. [Abstract] [Full Text] [PDF]

				C. F Singer, G. Hudelist, W. Lamm, R. Mueller, K. Czerwenka, and E. Kubista Expression of tyrosine kinases in human malignancies as potential targets for kinase-specific inhibitors Endocr. Relat. Cancer, December 1, 2004; 11(4): 861 - 869. [Abstract] [Full Text] [PDF]

				R. Fan, T. S. Kumaravel, F. Jalali, P. Marrano, J. A. Squire, and R. G. Bristow Defective DNA Strand Break Repair after DNA Damage in Prostate Cancer Cells: Implications for Genetic Instability and Prostate Cancer Progression Cancer Res., December 1, 2004; 64(23): 8526 - 8533. [Abstract] [Full Text] [PDF]